Last reviewed · How we verify
concomitant cisplatin
Cisplatin works by interfering with DNA replication, causing cell death in rapidly dividing cancer cells.
Cisplatin works by interfering with DNA replication, causing cell death in rapidly dividing cancer cells. Used for Ovarian cancer, Testicular cancer, Lung cancer.
At a glance
| Generic name | concomitant cisplatin |
|---|---|
| Sponsor | Groupe Oncologie Radiotherapie Tete et Cou |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which trigger DNA repair mechanisms and ultimately lead to cell death. This process is particularly effective in cancer cells, which have a high rate of cell division.
Approved indications
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Bladder cancer
- Stomach cancer
- Head and neck cancer
Common side effects
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
- Kidney damage
- Hearing loss
- Tinnitus
- Neurotoxicity
Key clinical trials
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC (PHASE3)
- Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) (PHASE2)
- Window of Opportunity in Preserving Laryngeal Function Trial (PHASE2)
- Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer (NA)
- Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia (PHASE2)
- Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) (PHASE3)
- IMPT Dose Escalation for NSCLC (HyDose) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- concomitant cisplatin CI brief — competitive landscape report
- concomitant cisplatin updates RSS · CI watch RSS
- Groupe Oncologie Radiotherapie Tete et Cou portfolio CI